Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$259.62
+4.3%		$252.15
$186.05
▼
$282.15
$15.52B0.39528,636 shs541,216 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$83.95
+1.2%		$78.25
$46.81
▼
$93.42
$16.22B0.962.21 million shs3.29 million shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$34.11
+3.5%		$28.49
$23.62
▼
$35.43
$20.55B0.832.41 million shs3.23 million shs
Grifols, S.A. stock logo
GRFS
Grifols
$8.25
+6.5%		$7.57
$6.96
▼
$10.32
$5.27B0.67661,940 shs926,381 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+4.33%+1.63%+3.12%+4.89%+33.40%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+1.17%+0.13%+3.95%+19.45%+71.64%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
+3.49%+8.56%+22.21%+26.10%+43.20%
Grifols, S.A. stock logo
GRFS
Grifols
+6.45%+4.04%+8.41%+1.73%-19.04%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$259.62
+4.3%		$252.15
$186.05
▼
$282.15
$15.52B0.39528,636 shs541,216 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$83.95
+1.2%		$78.25
$46.81
▼
$93.42
$16.22B0.962.21 million shs3.29 million shs
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$34.11
+3.5%		$28.49
$23.62
▼
$35.43
$20.55B0.832.41 million shs3.23 million shs
Grifols, S.A. stock logo
GRFS
Grifols
$8.25
+6.5%		$7.57
$6.96
▼
$10.32
$5.27B0.67661,940 shs926,381 shs
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+4.33%+1.63%+3.12%+4.89%+33.40%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+1.17%+0.13%+3.95%+19.45%+71.64%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
+3.49%+8.56%+22.21%+26.10%+43.20%
Grifols, S.A. stock logo
GRFS
Grifols
+6.45%+4.04%+8.41%+1.73%-19.04%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.05
Buy$300.3315.68% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.83
Moderate Buy$100.7920.06% Upside
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
2.85
Moderate Buy$39.5015.80% Upside
Grifols, S.A. stock logo
GRFS
Grifols
1.67
Reduce$10.0021.21% Upside

Current Analyst Ratings Breakdown

Latest GRFS, GMAB, BBIO, and ASND Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$319.00
8/17/2026
Grifols, S.A. stock logo
GRFS
Grifols
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D) ➝ Sell (D+)
8/14/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$280.00 ➝ $290.00
8/14/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$325.00 ➝ $341.00
8/14/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$345.00 ➝ $329.00
8/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$333.00
8/12/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$102.00 ➝ $107.00
8/12/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$104.00 ➝ $106.00
8/12/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$100.00 ➝ $111.00
8/11/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D) ➝ Sell (D-)
8/11/2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
(Data available from 8/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M19.88N/AN/A$26.78 per share9.69
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M32.69N/AN/A($12.81) per share-6.55
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$3.72B5.72$1.67 per share20.48$9.55 per share3.57
Grifols, S.A. stock logo
GRFS
Grifols
$7.42B0.76$1.51 per share5.47$13.63 per share0.61
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8920.1425.23N/A70.99%32.54%7.71%N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.57N/AN/AN/A-97.03%N/A-61.19%10/28/2026 (Estimated)
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$963M$1.2726.8621.061.9619.08%14.89%7.73%11/5/2026 (Estimated)
Grifols, S.A. stock logo
GRFS
Grifols
$454.82M$0.1943.426.300.285.54%6.21%2.39%N/A

Latest GRFS, GMAB, BBIO, and ASND Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/10/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5756-$0.78-$0.2044-$0.78$220.91 million$243.68 million
8/6/2026Q2 2026
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
$0.37$0.54+$0.17$0.4910$1.12 billion$1.16 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
N/AN/AN/AN/AN/A
Grifols, S.A. stock logo
GRFS
Grifols
$0.080.97%N/A42.11%N/A

Latest GRFS, GMAB, BBIO, and ASND Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
6/19/2026
Grifols, S.A. stock logo
GRFS
Grifols
special$0.09457/2/20267/2/20267/9/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.23
1.17
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
0.81
2.46
2.44
Grifols, S.A. stock logo
GRFS
Grifols
1.10
2.37
0.81

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
7.07%
Grifols, S.A. stock logo
GRFS
Grifols
N/A

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
1.54%
Grifols, S.A. stock logo
GRFS
Grifols
0.19%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400195.49 million167.67 millionOptionable
Genmab A/S Sponsored ADR stock logo
GMAB
Genmab A/S
3,029623.53 million613.93 millionOptionable
Grifols, S.A. stock logo
GRFS
Grifols
25,247680.58 million679.28 millionOptionable

Recent News About These Companies

Short Interest in Grifols, S.A. (NASDAQ:GRFS) Drops By 45.5%
August 17 at 5:39 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/short-interest-in-grifols-sa-nasdaqgrfs-drops-by-455-2026-08-17/
Grifols Announces Last Patient Last Visit in SPARTA, its Phase 3 Outcomes Study of Prolastin®-C in Patients With Emphysema Due to Alpha-1 Antitrypsin Deficiency
August 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/grifols-announces-last-patient-last-visit-in-sparta-its-phase-3-outcomes-study-of-prolastin--c-in-patients-with-emphysema-due-to-alpha-1-antitrypsin-deficiency-1036435305
Grifols Announces Completion of SPARTA Phase 3 Trial Follow-Up for Prolastin-C in Alpha-1 Emphysema
August 10, 2026  |  quiverquant.comQ
Janus Henderson Group PLC Has $26.35 Million Stock Holdings in Grifols, S.A. $GRFS
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-janus-henderson-group-plc-has-2635-million-stock-holdings-in-grifols-sa-grfs-2026-08-04/
Sei Investments Co. Sells 138,197 Shares of Grifols, S.A. $GRFS
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-sei-investments-co-sells-138197-shares-of-grifols-sa-grfs-2026-08-02/
Grifols Reshapes Board and Committee Leadership After Director Resignation
July 30, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/grifols-reshapes-board-and-committee-leadership-after-director-resignation?utm_source=marketbeat.com&utm_medium=referral
Grifols (GRFS) Q2 2026 Earnings Call Transcript
July 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/grifols-grfs-q2-2026-earnings-011235282.html
Grifols (NASDAQ:GRFS) Sees Large Volume Increase - Here's What Happened
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/grifols-nasdaqgrfs-sees-large-volume-increase-heres-what-happened-2026-07-29/
Grifols Half-Year 2026 Results: Profit Jumps as Refinancing Bolsters Balance Sheet
July 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/grifols-half-year-2026-results-profit-jumps-as-refinancing-bolsters-balance-sheet?utm_source=marketbeat.com&utm_medium=referral
Grifols, S.A. 2026 Q2 - Results - Earnings Call Presentation
July 28, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4926500-grifols-s-a-2026-q2-results-earnings-call-presentation
Grifols Q2 Earnings Call Highlights
July 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/grifols-q2-earnings-call-highlights-2026-07-28/
Grifols, S.A. (GRFS) Stock Rises on Q2 2026 Earnings
July 28, 2026  |  quiverquant.comQ
Grifols SA Q2 2026 earnings preview
July 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/grifols-sa-q2-2026-earnings-preview/ar-AA28OcoD
Grifols, S.A. $GRFS Shares Sold by Whitebox Advisors LLC
July 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-grifols-sa-grfs-shares-sold-by-whitebox-advisors-llc-2026-07-27/
Flat Footed LLC Buys 287,867 Shares of Grifols, S.A. $GRFS
July 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-flat-footed-llc-buys-287867-shares-of-grifols-sa-grfs-2026-07-27/
Grifols (GRFS) to Post Earnings on Tuesday
July 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/grifols-grfs-to-post-earnings-on-tuesday-2026-07-21/
Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
July 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/16/3328383/0/en/grifols-doses-first-patients-in-two-phase-3-trials-to-expand-indications-of-its-flagship-immunoglobulins.html
Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)
July 3, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4919718-grifols-operational-recovery-and-balance-sheet-improvement-support-a-return-to-buy-rating-upgrade
Grifols Reshapes Board and ESG Committee Following Director Resignation
June 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/grifols-reshapes-board-and-esg-committee-following-director-resignation?utm_source=marketbeat.com&utm_medium=referral
Grifols (GRFS) Launches FESILTY in the U.S. for Congenital Fibrinogen Deficiency Treatment
June 19, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/grifols-grfs-launches-fesilty-u-165231770.html
Grifols Shareholders Approve 2025 Accounts and July Dividend, Renew Deloitte Mandate
June 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/grifols-shareholders-approve-2025-accounts-and-july-dividend-renew-deloitte-mandate?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$259.62 +10.77 (+4.33%)
Closing price 08/19/2026 04:00 PM Eastern
Extended Trading
$256.00 -3.62 (-1.39%)
As of 05:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$83.95 +0.97 (+1.17%)
Closing price 08/19/2026 04:00 PM Eastern
Extended Trading
$83.02 -0.94 (-1.11%)
As of 04:54 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Genmab A/S stock logo

Genmab A/S NASDAQ:GMAB

$34.11 +1.15 (+3.49%)
Closing price 08/19/2026 04:00 PM Eastern
Extended Trading
$33.78 -0.33 (-0.96%)
As of 05:42 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Grifols stock logo

Grifols NASDAQ:GRFS

$8.25 +0.50 (+6.45%)
Closing price 08/19/2026 04:00 PM Eastern
Extended Trading
$8.26 +0.01 (+0.12%)
As of 05:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas